InnoPharma Licensing LLC v. AstraZeneca AB IPR2017-00904
`
`WWWSITIITOMGSLGUSCOI
`
`AstraZeneca Exhibit 2044 p.
`
`1
`
`&,
`
`%
`
`

`

`INNOVATIVE RESEARCH OF AMERICA!=aeaeeeeEeee)
`
`Mostscientists agree that the three essential parameters in the success of a biomedical
`experimentare:
`
`A. Thescientific problem formulated in a defined question.
`
`B. The laboratory animal, healthy and untraumatized.
`
`C. The process of active product delivery; the most problematic variable of all three!
`
`For a third of a century, Innovative Research of America has assumedthe leadership role
`in improved time release technology. The main missionis to standardize the technology of
`drug delivery. Our proven Time Release Hormone and DrugPellets help investigators take
`charge of product delivery and expandtheir abilities to do meaningful and reproducible
`research.
`
`ADVANTAGESOF THE PELLET DELIVERY oTLEM
`cs zrenyadministerpelletforasimplessubcutaneousimplantation,eo
`
`|
`
`Ushering In The Age OfInnovative Research
`
`AstraZeneca Exhibit 2044 p. 2
`
`

`

`HORMONE AND DRUG PELLETS FOR BIOMEDICAL RESEARCH
`
`LL]———_—_———SSSee
`
`Since it is not easy to administer drugs and hormonesorally to research animals,
`several delivery methods have been devised as alternatives. However, most scientists
`continue to labor with unreliable injectables to conducttheir research.
`
`Because of this inadequacy, biomedical research is as confusingasit is challenging
`andasfrustrating as itis creative. The optionsof scientists to address scientific questions
`are not only dependent, but are also limited by the process of active productdelivery.
`Traditionally, product delivery into the experimental animal has been the procedure most
`subject to variables and the mostdifficult to standardize effectively. The very process
`of having to accurately administer drugs to experimental animals can becomea logistic
`nightmarefor scientists.
`
`CHANGING THE TIME COURSE OF DRUG DELIVERY
`
`F ns.ik ‘Sit
`ne19
`!ESSNe
`ng!
`
`WeTell Time-Release Pellets What Time It Is
`
`AstraZeneca Exhibit 2044 p. 3
`
`

`

`|§PQA Tasce or Contents
`
`Find a Productin this Catalog..........ccsssssssesssssccssssneessnnenessccccesnnessene 5
`Ordering Information / General Policy & Terms................ 6, 7, 44, 84
`Sales Of ANADOUC SterolSy iva eenssscasssncianisassasgcascguasccassecbaunnesssncess sin 8
`
`CATAGOrY INGDOKsccassssics sos srtnsscxaseonnnncveanicacnesscsqesasenannnsnsddscassbanneseess 10-15
`Alkaloids
`Estrogens
`Amino Acids
`Fatty Acids
`Androgens
`Nucleotide Related Products
`Antibiotics
`Progestins
`Anti-inflammatory Agents
`Prostaglandins
`Anti-Neoplastics
`Thyroids
`Catecholamines
`Vitamins
`Corticoids and Diuretics
`
`We Add Time To Your Day
`
`Placebo PelletsInformation/ P
`
`Pasheteppuisuauivenaas
`
`i9
`
`Alphabetical Product: LISTING wiriiiieniccicsascsccmsnscncuevenennsnnesnss vs 21-42
`Stock Pellet Price SCHECUIeS................ccceecceeeeccceecccceeeeeneenenserees 45-71
`
`Pellets for Immuno-Deficient Mice
`
`178-Estradiol / Tamoxifen & Sample References...........0s00000 73-77
`Androgens / Anti-Androgens & Sample References............... 78-80
`Trochar & RecommendedImplantation Procedure................ 81, 123
`Doxycycline & Tetracycline Pellets in MiCe.........cccccssseeeeeeees 85-86
`Hormone + Hormone Pellets .............ccccccsseseseecssssceeeseeeeesseeeeseees 89-92
`
`Cureteey Pel Gia sssccscsaa caticetassesaasstatvsisiisaazazamvaninaxttacassevesantiaaaasssis 93-108
`
`Selected References.............-:..::::sssssesseseusseeesseeeeccceeceeesessnnnens 109-122
`
`Order FOPMS ovivsvsvnicsessossnsscasassscosonsnacsssassensssstentonvernese Back of Catalog
`
`PEUOTIS oescccesisncnsanoossaasassecossconnsncnnnavassssssscaacuniansvedade Inside Back Cover
`
`*Forfurther assistance, view our website at:
`www.innovrsrch.com
`
`AstraZeneca Exhibit 2044 p. 4
`
`

`

`PRODUCT DESIGN AND FEATURES
`
`AigAMAN ee
`
`rely
`A
`i,
`Sa
`mE
`lea ri eee
`
`ait
`
`The Pellet Implantation Methodology provides solutionsto:
`
`.. consistency in timing repeated product administrations.
`
`... controlling the amountof product administered.
`
`... Stability of the product preparation.
`
`.. Safety of the experimenter.
`
`.. neurophysiological trauma to the animal from excessive handling.
`
`.. freeing valuable research time.
`
`.. eliminating unnecessary and unstimulating laboratory practices.
`
`Scientists from several research disciplines have documented in scientific literature that
`our Pellet Delivery System is effective, consistent, reproducible, economical, reliable, and
`safe for the animal. See Selected References on pages 109-122.
`
`Only TimeRelease Pellets Really Know What TimeIt Is
`
`AstraZeneca Exhibit 2044 p. 5
`
`

`

`PRODUCT SPECIFICATIONS
`
`AVAILABLE SHAPES AND SIZES
`
`Stock pellets are round and range in diameter from 1/8” (3 mm) to 1/2”(1.25 cm) depending on the
`dose and the release rate. Our Custom Pellets Department will also design various pellet shapes and
`smaller sizes (Page 94) to meet your research needs. Please refer to the Custom Pellets section on pages
`93-108.
`
`AVAILABLE DOSAGES
`
`Mostof the stock products inthis catalog are available in 20 different dosages ranging from | microgram
`(0.001 mg) per pellet up to 200 milligrams (200 mg)perpellet within the specified release rate. Doses of
`pellets listed in this catalog reflect the total amount of net active product released overthe indicated
`period oftime.
`
`AVAILABLE RELEASE RATES
`
`Stock products are designed to release continuously for 21 days, 60 days, or 90 days. Please refer to our
`Custom Pellets section on pages 93-108 for other: release rates tailored for the duration of the experiment.
`
`AVAILABLE PRODUCTS
`
`In our continuing quest to make available new stock items that are particularly in demand, we have added
`several products to the original categories. In addition to the listed pelletized products, Innovative
`Research of Americahas an efficient Custom Pellets Department to prepare products that are notavailable
`as stock items.
`
`SELECTED REFERENCES
`
`A sample of publications that employed ourdelivery system in a broad spectrum of products can be found
`on pages 109-122.
`
`Consistent Dose-Dependent Release
`
`AstraZeneca Exhibit 2044 p. 6
`
`

`

`FINDING A PRODUCTIN THIS CATALOG
`aes
`
`The PRODUCTSin this catalog are arranged in ALPHABETICAL ORDERandare identified by
`a CATALOG NUMBERand a PRICE SCHEDULEwith a PAGE NUMBER.
`The catalog numberandprice schedulereflecta release rate of 21 days, 60 days, or 90 days.
`To illustrate with 178-Estradiol as an example:
`
`EXAMPLE
`
`Product
`
`21-Day Release
`Catalog
`Price Schedule/
`Number
`Page Number
`
`60-Day Release
`Catalog
`Price Schedule/
`Number
`Page Number
`
`178 - Estradiol
`
`E- 121
`
`B-21/48
`
`SE- 12]
`
`B-60/49
`
`NE - 121
`
`B-90/50
`
`90-Day Release
`Catalog
`Price Schedule/
`Number
`Page Number
`
`
`
`
`
`The above example indicates that 176-Estradiolis available in three release forms each having a
`different catalog numberandprice code,i.e.
`
`E - 121 is a 21-day release form with a price code of B-21, found on page 48.
`SE - 121 is a 60-day release form with a price code of B-60, found on page 49.
`NE- 121 is a 90-day release form with a price code of B-90, found on page 50,
`
`The PAGE NUMBERnextto the PRICE SCHEDULEindicates the page where the actual price
`for the product appears.
`
`Whenordering please use the PRODUCT NAME, CATALOG NUMBER, RELEASE
`RATE and DOSE. Most products are available in 20 different dosages. Products are sold in
`Lots of 25, 50, 100, and 200 pellets. Please indicate the quantity of pellets being ordered,
`
`Beginning on Page 10 wehave grouped someof our catalog itemsin related categories
`alphabetically. We hopethe listing will help in noting items of potential interest.
`
`Time-ReleasePellets...Always On Time
`
`AstraZeneca Exhibit 2044 p. 7
`
`

`

`
`
`
`
`° Mail
`Innovative Research of America,Inc.
`2 North Tamiami Trail
`Suite 404
`Sarasota, Florida 34236 USA
`
`* Internet / E-Mail
`http://www.innovrsrch.com (website)
`pellets@innoyrsrch.com (e-mail)
`
`IRA’s website features our company profile,
`the latest product technology and on-line ordering.
`
`« Phone
`(941) 365-1406
`(941) 365-1506
`(800) 421-8171 (USA/Canada)
`
`@) AMERICAN EXPRESS
` 2) ViSAAND MASTERCARD ACCEPTED.
`° Fax'visa’_| Purchase Order Formsarein the backof the
`eS catalog.
`(941) 365-1703
`(941) 365-1803
`(800) 643-4345 (USA/Canada)
`(800) 648-6030 (USA/Canada)
`
`Custom Pellets Information Form on page 95.
`
`THE DIFFERENCE \S
`CONSISTENCY AND UNIFORMITY.
`
`Bank Wire Payment Information
`Payment via bank wire should be directed as follows:
`
`BB&T Bank
`
`1800 Second St., Suite 100
`Sarasota, Florida 34236
`
`Routing # (ABA) 263191387
`Electronic Transfers # 263191387
`
`Swift Code: BRBTUS33
`
`In favorof:
`Innovative Research of America
`
`2 North TamiamiTrail
`Suite 404
`
`Sarasota, FL. 34236
`Checking Account: #0000147816154
`
`Ushering In The AgeOfInnovative Research
`
`AstraZeneca Exhibit 2044 p. 8
`
`

`

`POLICY
`
`GENERAL POLICY AND TERMS
`
`lr,
`
`ase
`C
`phattances
`
`‘dersshippedout ideof the
`
`AstraZeneca Exhibit 2044 p. 9
`
`

`

`SALE OF CONTROLLED ANABOLIC STEROIDS
`within the United States
`
`(Telephone orders will not be accepted - orders & copy.of DEA license may be mailed or faxed)
`Before we can prepare any orders of Anabolic Steroid Pellets, the Drug
`Enforcement Administration (DEA) requires us to obtain:
`1. A valid photocopyofthe investigator’s DEA Registration
`containing Schedule 3N.
`2. A written Purchase Order showingthe investigator’s DEA
`Registration Numberand proper shipping address.
`
`CONTACT INNOVATIVE RESEARCH OF AMERICA
`
`BY PHONE, MAIL, FAX OR E-MAIL
`
`FOR MORE ORDERING INFORMATION - SEE PAGE 6
`
`SALE OF CONTROLLED ANABOLIC STEROIDS
`outside the United States (International)
`——aSeeeeeeeS
`
`WE NO LONGERSHIP ANABOLIC STEROIDS
`
`outside the United States (International)
`
`DEA Controlled Anabolic Steroids
`
`Androstenediol
`
`19-Nortestosterone 17-Decanoate
`
`Androstenedione
`5a-Dihydrotestosterone
`Fluoxymesterone
`
`Mesterolone
`
`Mesterone
`
`Methandriol
`Methandriol Dipropionate
`19-Nortestosterone
`
`19-Nortestosterone 17-Dipropionate
`Stanozolol
`Testosterone
`
`Testosterone Acetate
`
`Testosterone Benzoate
`
`Testosterone Cypionate
`Testosterone Enanthate
`Testosterone 17&-Hemisuccinate
`
`nig
`ih
`
`Time Release Pellets ...Always On Time
`
`Testosterone Propionate
`
`AstraZeneca Exhibit 2044 p. 10
`
`

`

`Nelad
`
`=
`
`See pages 73-80 regarding
`Hormone/Anti-Hormone products
`for Immuno-Deficient Mice
`and specific references.
`
`Your Research Time Is Under Your Control
`
`AstraZeneca Exhibit 2044 p. 11
`
`

`

`CATEGORY INDEX
`
`ALKALOIDS
`
`COr
`
`Onthe following 6 pages, we have grouped some of our Catalog itemsin related categories.
`Hopefully this listing will help in noting items of potential interest.
`
`
`
`10
`
`AstraZeneca Exhibit 2044 p. 12
`
`

`

`
`
`

`

`
`
`12 AstraZenecaExhibit 2044|
`
`It’s Time For Clear, Consistent Results
`
`
`
`
`
`

`

`CATEGORY INDEX (continued)
`
`WhenReliability Counts
`
`AstraZeneca Exhibit 2044 p. 15
`
`

`

`CATEGORY INDEX (continued)
`
`AstraZeneca Exhibit 2044 p. 16
`
`

`

`CATEGORY INDEX (continued)
`
`Consistent Results With Consistent Relea:
`
`AstraZeneca Exhibit 2044 p. 17
`
`

`

`ADVANTAGES OF OUR MDD PELLET SYSTEM [—
`
`« Saves time
`
`+ Ready-to-implant
`
`¢
`
`Insures controlled product release overtime
`
`|
`
`« Avoids “peak and valley” effects
`
`« Guarantees consistent product preparation
`
`« Extends productlife against spontaneous breakdown
`
`« Extends productlife against host-related breakdown
`
`« Minimizes experimental variables
`
`¢
`
`Insures safety of the researcher
`
`« Reduces neurophysiological trauma to the animal/
`
`no.~-cessive handling
`
`« Generates more meaningful and reproducible results
`
`¢ Superior to conventional delivery methods
`
`« Enhances experimentalefficiency
`
`« Frees valuable time for creative research
`
`« Saves money
`
`
`
`AstraZeneca Exhibit 2044 p. 18
`
`

`

`a
`
`
`PELLETS
`
`PLACEBO / CONTROL
`
`
`
`
`
`
`MatchingPlacebopellets contain all the components of the hormoneor drugpellet exceptthe active
`t
`productitself. The carrier-binder excepients of the matrix include Cholesterol, Lactose, Celluloses,
`Phosphates and Stearates.
`
`
`
`Stock Placebopellets are available in 20 different doses corresponding to those of active product
`pellets. Each doseis offered in either 21 Day, 60 Day, or 90 Day Release form.
`
`|
`
`Although the matrixes in Placebo pellets have a different composition for different active products,
`they are all assigned the same catalog numberandare offered at the same price schedule.
`
`Wheninquiring or placing an order, please specify the active product you wish to correspond the
`Placebopellets for. Please see the following examples:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`| NC-111
`
` *Pleaseinquire directly with us iffurther assistance is required regarding a productofinterest.
`
`Catalog No.
`
`Peteayes
`
`Dose in mg/pellet
`
`Release in Days
`
`C-111
`SC-111
`
`Placebo for “Active Product”*
`Placebo for “Active Product’”*
`Placebo for “Active Product’’*
`
`____ mg/pellet
`mg/pellet
`mg/pellet
`
`21 Day
`60 Day
`90 Day
`
`*In place of “Active Product” specify the hormoneor drug you areutilizing in your study.
`
`The following three pages are universal dose /price schedulesin all three release rates (21 Day, 60
`Day, and 90 Day) and are applicable as a matching Placebo for all products in the catalog except
`special physical size and preparations (page 94) which can be found under the Custom Pellet section
`on pages 93-108.
`
`|
`
`
`
`AstraZeneca Exhibit 2044 p. 19
`
`

`

`
`
`AstraZeneca Exhibit 2044 p. 20
`
`

`

`
` 0.001
`
`$697
`
`canis
`
`PRICE SCHEDULE
`Ca No. C-et
`
`$1362
`
`$2649
`
`=|
`
`0.010
`0,025
`0.05
`0.1
`0.25
`0.5
`1.5
`2.5
`5.0
`7.5
`10.0
`15.0
`25.0
`35.0
`50.0
`75.0
`100.0
`150.0
`200.0
`
`$697
`$697
`$697
`$697
`$697
`$697
`$697
`$697
`$697
`$702
`$702
`$702
`$707
`$707
`$707
`$707
`$718
`$718
`$723
`
`$1362
`$1362
`$1362
`$1362
`$1362
`$1362
`$1362
`$1362
`$1362
`$1379
`$1379
`$1379
`$1386
`$1386
`$1386
`$1386
`$1406
`$1406
`$1415
`
`$2649
`$2649
`$2649
`$2649
`$2649
`$2649
`$2649
`$2649
`$2649
`$2674
`$2674
`$2674
`$2674
`$2674
`$2674
`$2674
`$2734
`$2734
`$2744
`
`$4816
`$4816
`$4816
`$4816
`$4816
`$4816
`$4816
`$4816
`$4816
`$4858
`$4858
`$4858
`$4875
`$4875
`$4875
`$4875
`$4945
`$4945
`$4964
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available, PLEASE INQUIRE.
`
`Sixty and Ninety day price schedules are on the following two pages.
`
`
`
`AstraZeneca Exhibit 2044 p. 21
`
`

`

`
`
`PRICE SCHEDULE
`
`Cat. No. SC-111 200.0
`
`$5197
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available, PLEASE INQUIRE.
`
`
`
`AstraZeneca Exhibit 2044 p. 22
`
`

`

`2.a
`
`Sor
`Pa
`
`
`
`PRICE SCHEDULE
`
`|
`available. PLEASE INQUIRE.
`
`A combination of multiple dosages in one lot, for any specified product,is also
`
`See-
`i
`a
`
`7
`
`AstraZeneca Exhibit 2044 p. 23
`
`

`

`
`
`
` TIME RELEASE PELLETS For
`BIOMEDICAL RESEARCH IN
`
`
`One-Step.Continuous Release Pellets Arethe Best Alternative
`
`Time Release Pellets
`for Biomedical Research from IRA
`DOSE
`
`Day 1
`
`Day 2
`
`Day 3
`
`LABORATORY ANIMALS
`Multi-StepInjections.\ reaContinuous Painin DRUG DELIVERY
`RELEASE
`
`
`
`
`MW
`
` ~
`''
`
`
`TIME
`
`
`
`Our Team atIRA is working
`; S L a 2qT :
`|
`pi ae
`ae
`
`
`mel
`to meet the responsibility that
`|
`
`G ie ie
`aay I i a
`Innovative Science demands
`
`
` ‘5 E and Innovative Scientists
`
`
`oe
`ae
`
`|
`
`e
`
`LI
`
`
`
`‘a5 deserve.
`
`
`
`AstraZeneca Exhibit 2044 p. 24
`
`

`

`INTRODUCTION TO
`
`ALPHABETICAL PRODUCT LISTING
`
`The PRODUCT NAMES in this catalog are arranged in ALPHABETICAL
`ORDER and are identified by their individual CATALOG NUMBERSincluding a
`PRICE SCHEDULEand corresponding PAGE NUMBER.The catalog numberand
`eCYCeeeee eoeeCeerLeee
`
`To illustrate with Acetazolamide as an example, please viewthe following table:
`
`iaM@yeTit
`
`21 DayRelease
`
`60 Day Release
`
`90 Day Release
`
`Acetazolamide
`
`Catalog
`Number
`D-111
`
`Price Schedule/
`Page Number
`C21/51
`
`Catalog
`Number
`SD-111
`
`Price Schedule/
`Page Number
`C60 / 52
`
`Catalog
`Number
`ND-111
`
`Price Schedule/
`Page Number
`C90 / 53
`
`MaximumFlexibility
`
`Whenplacing an order,please include the PRODUCT NAME, CATALOG NUMBER, DOSE IN
`MG/PELLETand RELEASE RATE.Mostof our productsare available in 20 different doses.
`Products are normallysold in lots of 25, 50, 100, and 200 pellets. Please indicate the quantity
`Oe aeRO Mei(oese
`Beginning on page 10, we have grouped some of our catalog items by related categories
`alphabetically. We hopethe listing will help in noting items of potential interest.
`
`The above exampleindicates the stock product Acetazolamideis available in three release
`forms each having a different catalog numberand price code,i.e.
`
`D-111 is a 21 Day Release form with a price code of C-21, found on page 51.
`SD-111 is a 60 Day Release form with a price code of C-60, found on page 52.
`ND-111 is a 90 Day Release form with a price code of C-90, found on page 53.
`
`The PAGE NUMBERnextto the PRICE SCHEDULEindicatesthe page wherethe actual
`price for the product appears.
`
`AstraZeneca Exhibit 2044 p. 25
`
`

`

`
`
`AstraZeneca Exhibit 2044 p. 26
`
`

`

`ALPHABETICAL PRODUCT LISTING
`aSSS
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release|60-Day Release|90-Day Release
`> Catalog Price Schedule/|Catalog Price Schedule/|Catalog Price Schedule/
`
`Product
`Number Page Number
`Number Page Number
`Number Page Number
`
`Acebutolol B-21/48|SC-101 B-60/49|NC-101- B-90/50
`
`
`
`
`ne Acetamidofluorene(2“AAF)
`
`
`
`
`
`
`
`
`
`Acetarsone B-21/48|SB-165 B-60/49|NB-165 B-90/50
`
`D-90/56
`
`Acetopromazine B-60/49|NC-102- SC-102 B-90/50
`
`
`
`
`i ‘AcetylL-Carnitine oe | \ or: : - E -2 1803) OMe 7:
`60 49
`(50.
`i N-ae-L-ae
`|
`- |
`B-60/49 )
`
` c-2151| St 113 C6 | 5 |.
`| K112
`fe
`~ rans-AconiticAcid
`
`
`Aconitine E-21/57|SK-113 E-60/58
`
`B-21/48
`
`C-90153
`C-60/52
`SN-111
`C-21/51|
`Adenosine
`|e1te B21me] serieB09| N6116 B-90/50
`Adrenal
`
`p.21/48|SG-117 B-60/49 B-90/50
`
`“H-21i60| SZ-180 H-60/61| NZ-180H-90/62
`
`
`
`B-21/48|SC-135 B-60/49 B-90/50
`
`
`
`
`
`B-21/48|SQ-111 B-60/49 B-90/50
`
`
`
`Reeonine
`
`21/1 | sat21 C6052 | NO121C-90/53
`
`
`
`
`
`Albendazole B-21/48|SB-166 B-60/49 B-90/50
`
`
`
`pees
`
`mona ome ae 51
`
`160061 i : f i: 5 : .062
`
`
`
`B-21/48|SI- B-60/49 B-90/50
`
`
`
`A21145| SA-103 A60/46 “NA103- -A90/47:
`:
`lloxan
`
`
`Alprenolol D-21/54|SC-431 D-60/55|NC-431
`
`21
`
`AstraZeneca Exhibit 2044 p. 27
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`21-Day Release|60-Day Release|90-Day Release
`Catalog Price Schedule/|Catalog Price Schedule/|Catalog Price Schedule/
`Product
`Toa eee Number Page Number
`Number Page Number
`
`
`
`Althiazide B-21/48|SA-104 B-60/49|NA-104 B-90/50
`
`
`
`
`
`
`
`|Apntdne9 : - B-21/48|SB-167 B-60/49|NB-167 _B-90/50
`
`
`
`
`
`
`
`
`
`Amcinonide A-21/45|SG-118 A-60/46|NG-118 A-90/47
`
`— Amiloride aa B-60/49|ND-181oat - B-21/48| SD-181 _B-90/50
`
`
`
`
`
`
`
`
`~ Aminoacetonitrie B-21/48|SA-105 B-60/49|NA-105 B-90/50
`
`
`
`
`~o-Aminoacetophenone A-60/46|NA-106| A106 A-21/45| SA-106° A-90/47
`
`
`
`m-Aminoacetophenone B-21/48|SA-107 B-60/49|NA-107 B-90/50
`
`
`_p-Aminoacetophenone B-21/48|SA-108 B-60/49\| NA-108 —B-90/50
`
`
`
`
`
`
`‘Aminoglutethimide D-60/55|NG-281D-21/54| SG-281 D-90/56
`
`
`
`__6-AminopenicillanicAcid B-21/48|SB-111oof B-60/49 | NB-111 B-90/50
`
`
`
`
`Aminophylline C-21/51|SC-125 C-60/52|NC-125 C-90/53
`
`
`
`Senos B-21/48| B-60/49|NA-109SA-109 B-90/50
`
`
`
`
`Amiodarone B-21/48|SA-112 B-60/49|NA-112ao B-90/50
`
`
`
`
`Amitriptyline- ee : C-60/52|NC-451 €-21/51| SC-451 —C-90/53
`
`
`
`“Amoxicilin B-21/48|SB-112 B-60/49|NB-112 B-90/50
`“AmphotericinB
`| B413
`—
`-p-21/54| $B-113
`D-60/55 | NB-113
` D-90/56
`B-21/48|
`SB-114
`B-60/49 | NB-114
`B-90/50
`21/45 | SC-107 60/46| NC-107 A-90/47
`
`
`B-21/48|SA-131 B-60/49|NA-131 B-90/50
`8.208| SA-121
`B.60/49|NA-121 B-90/50
`
`
`
`~c-2tist| C-60/52|NA-141SA-141 C-90/53
`_D-21/54| SA-101
`D-60/55 | NA-101
` D-90/56
`
`
`B2148| SK-114 B-60/49|NK-114 B-90/50
`- B-21/48| SK-115 B-60/49|
`| Anscdie
`NK-115
`_B-90/50
`
`
`
`
`
`“Antazoline c-60/52|NC-461| c-21is1| sc-461 C-90/53
`
`
`SAeiiened | ‘A-21/45| SF-111 A-60/46|NF-111 A-90/47
`
`
`“Arachidonic Acid — es A-21/45|SF-161 A-60/46|NF-161 A-90/47
`
`22
`
`AstraZeneca Exhibit 2044 p. 28
`
`

`

`
`
`Arecoline C-21/51|SK-116 C-60/52|NK-116- C-90/53
`
`
`
`-
`NO-151
`canst | 4 7 C-60/52
`- 5
`|
`‘Afatnins
`BG RARAOEE
`
`
`
`D-Asparagine -21/51| sa-t61 c-60/52|Na-161| ase: C-90/53
`
`a ¢-60/52|Na-181 C-90/53c-21/51| sa-181
`
`
`-Aspartic Acid
`ee eee SQ-191 C-60/52_ “NQ-191 C9053
`
`
`
`
`
`Aspirin C-60/52|NX-121: c-21151} Sx-121 C-90/53
`Aienol
`B-21/48| SC-221 8-60/49 | NC-221_B-90/50
`Atropine
`¢-21/51| SK-117 ¢-60/52 | NK-117
`C-90/53
`4
`|
`_ Atropine Methyl Bromide
`18 C2161| SK-118 C-60/52 |NK-118 C-90/53
`
`
`
`8-Azaadenine B-21/48|SN-121 B-60/49|NN-121 B-90/50
`
`E_S-Azaoytidine A-21/45|SN-131 A-60/46 | NN-131. A-90/47
`
`
`
`
`
`5-Azacytosine C-60/52|NN-141; c-21/51| SN-141 C-90/53
`
`
`8 C-21/51|SN-151 C-60/62 | NN-151 C-90/53
`
`
`
`c-21/51| c-60/52|NN-161sN-161 C-90/53
`B-21/48 | SN-171 . B-60/49 | NN-171 B-90/50
`
`
`
`
`
`B-21/48|SN-181 B-60/49|NN-181 —B-90/50
`
`B-21/48| SN-191 B-60/49 | NN-191. B-90/50
`
`
`
`c-21/51| C-60/52|NN-201SN-201 C-90/53
`B-21/48 | SN-211 B-60/49| NN-211B-90/50
`
`
`B-21/48|SB-115 B-60/49|NB-115 _B-90/50
`A-21/45 |
`SB-110 A-60/46 | NB-110A-90/47.
`
`
`p-21/54| SB-116 D-60/55|NB-116 D-90/56
`-D:21/54| SB-117 — D-60/55 | NB-117 D-90/56.
`¢-21/51| SK-119
`C-60/52
`
`Berberine
`
`|
`
`23
`
`AstraZeneca Exhibit 2044 p. 29
`
`ALPHABETICAL PRODUCT LISTING
`olaaaaEE
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release|60-Day Release|90-Day Release
`
`7 Catalog Price Schedule/|Catalog Price Sehedule/|Catalog Price Schedule/
`
`
`iiaietiias Number Page Number|Number Page Number MT
`
`
`
`
`
`
`
`|NK-119 C-90/53
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release|60-Day Release|90-Day Release
`
`oduc Catalog Price Schedule/|Catalog Price Schedule/|Catalog Price Schedule/
`
`aRiel
`Number Page Number
`Number Page Number
`Number Page Number
`
`
`
`
`
`Betamethasone _L-21/63|SG-191 L-60/64|NG-191G-191 —L-90/65
`
`
`
`
`epoldine™ 7 C-60/52|NK-120K-120 C-21/51| SK-120 C-90/53
`
`8-Bromoadenosine 3:5’ Cyclic Monophosphate|N-221 SN-221 M-60-67|NN-221 M-90/68 M-21/66|
`
`
`
`
`
`Bromocriptine Mesylate E-21/57|SC-231| C-231 _E-60/58 | NC-231 E-90/59
`
`
`
`
`
`
`5-Bromo-2'-Deoxyuridine (erDu) B-21/48|SN-231 B-60/49|NN-231N-231 —B-90/50
`
`
`
`
`es Bucne2 | K-122 C-60/52|NK-122 C-21/51| SK-122 C-90/53
`
`
`
`
`Busulfan (Myleran) B-21/48|SZ-130 B-60/49|NZ-130Z-130 B-90/50
`
`
`
`
`(hehe —-C-21/51.|SC-191. C-60/52|NC-191|C-191 C-90/53
`
`
`
`
`Calycanthine _B-21/48|SK-123 B-60/49|NK-123K-123 _B-90/50
`
`
`
`“Camptothecin E-60/58|NC-116—E-90/59.eet eas | c-116 E-21/57.| SC-116
`
`
`Captopril B-21/48.|SC-117 B-60/49|NC-117_B-90/50C-117
`
`
`
`
`"Carbamazepine (ea 6.21/51|SC-113._C-60/52|NC-113‘| C113 C-90/53
`
`
`
`
`
`
`
`Carbinoxamine _C-21/51|SC-471 _C-60/52|NC-471C-471 C-90/53
`
`
`
`
`
`: “L-Carnitine oe 7 V-271_C-21/51|SV-271 —C-60/52|NV-271 _C-90/53
`
`
`
`
`
`
`
`
`
`
`
`B-Carotene C-21/51|SV-215 C-60/52|NV-215V-215 C-90/53
`
`
`
`: Casodex(uicalutamide) A gs 2 ie
`
`Z i We can'custommake any doseand any release time. (PLEASE INQUIRE)
`
`
`
`
`
`
`
`Cefadroxil A-21/45|SB-170 A-60/46|NB-170B-170 A-90/47
`
`
`
`‘NB-171 ; A-90/47
`—A-60/46
`a Cefamandole oo Ban A215. SB-171
`
`
`
`
`
`Cefazolin 60/46|NB-172B-172 A-21/45| SB-172 A-90/47
`~Ceimetazole 8 . eo :
`| B73. 21/45| $B-173
`A60/46
`| NB-173 A-90/47.
`
`
`
`
`
`Cefoperazone A-21/45|SB-174 A-60/46|NB-174B-174 A-90/47
`Cefotaxime=i“ assi(s;*é=‘~*~*é‘*dSBS ANAS|B75 AGOAG|NB-175 A-90/47
`
`
`
`
`
`Cefoxitin A-21/45|SB-176 A-60/46|NB-176B-176 A-90/47
`—Cefsulodin = titi‘SCS;C* CBT AS|SB177 © A-60/46 | NB-177 90/47
`
`—B-90/50
`
`
`
`
`
`
`
`Ceftriaxone A-21/45|SB-178 A-60/46|NB-178B-178 A-90/47
`
`
`
`_Centrophenoxine(Mesiofenoxate) -¢-21/51|SC-115 C-60/52|NC-115| C15 _C-90/53
`
`
`
`
`
`Cephalexin B-21/48|SB-118 B-60/49|NB-118B-118
`
`
`
`24
`
`AstraZeneca Exhibit 2044 p. 30
`
`

`

`ms
`
`ALPHABETICAL PRODUCT LISTINGPe
`
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release|60-Day Release|90-Day Release
`
`meet
`
`i
`
`“ See el ipa Seg ence tela cP re eee Rl
`
`ereee ne
`
`ASI
`
`. Catalog Price Schedule/|Catalog Price Schedule/|Catalog Price Schedule/
`
`
`
`Product Number Page Number|Number Page Number Number Page Number
`
`
`
`
`ecu D-21/54|SB-119 D-60/55|NB-119B-119 D-90/56
`Cephapiri
`-
`B-21/48
`=
`-
`NB-121
`B-90/50
`,- Chlorambucil Sepa eae a - a ZA i A245 :
`:
`
`140
`
`A-60
`
`
`
`
`
`Chloramphenicol C-21/51|SX-131 C-60/52|NX-131- C-90/53
`EChioramphenicolBase = |BZ3 C2161| SB-123C-60I52
`|
`53
`
`
`
`Chlorcyclizine B-21148|SC-145445 B-60/49 | NC-145 B-90/50
`
`=Chlormadinone Acetate
`let 28 [ee A215 “SpP-221 A60/46 NP-221 “A90/47
`
`
`
`
`Chloroquine C-21/51|Sl-112- C-60/52
`P Chlorothiazide | e1ss
`carer | sc155 cena|Ne155C9063
`
`
`
`Chiorotiianisene C-21/51|SE-201- C-60/52 C-90/53
`
`=Chlorpheniramine
`| B-124— C-21/51 . SB- 124 C-60/52 /NB-124- 90153.
`
`
`
`Chlorpromazine C-21/51|SC-241: C-60/52 C-90/53
`
`
`
`FEchiorthalidone B-21/48| SC-175 B-6049|NC-175B.90/50,:
`
`
`
`Chlorzoxazone C-21/51|SC-1855 C-60/52 C-90/53
`
`Recimetidine
`372
`B.21/48.|
`$C-372 B-60/49 | NC-372 8.90/50
`
`
`
`Cinchonidine c-21/51|$B-1544 C-60/52 | C-90/53
`
`
`
`Ecinnarizine C-2161 | $B-125 C-60/52|NB125 C-90/53125
`
`
`
`
`
`Clemastine B-21/48|SC-120; 3 B-60/49 NC-12 B-90/50
`
`[Clomizole
`C119
`¢-21/61|
`sc-119
`c-6062 | Ne-119 C-90153
`
`
`
`Clenbuterol H-21/60|SC-118: H-60/61 H-90/62
`
`
`
`
`Eelofoctol C2151|SC-104104 C-60/52 | NC-104 C-90/53
`
`
`
`
`Clomiphene CCitrate B-21/48|SP-211E B-60/49 B-90/50
`
`
`
`
`ci{omipramine C-21/51|SC-103103 C-60/52 | +103 C-90/53
`
`
`
`Clonidine B-21/48|SC-251; B-60/49 : B-90/50
`
`
`
`
`
`
`
`
`Clopamide B-60/49||| Erte B-21/48.| SC-105 ( 5. B-90/50.
`
`B-90/50
`
`
`
`
`
`
`
`Clotrimazole B-21/48|SB-126: B-60/49 ‘
`
`
`
`25
`
`AstraZeneca Exhibit 2044p. 31
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`
`
`H-90/62
`
`
`
`
`
`
`
`60-Day Release|90-Day Release
`21-Day Release
`
`
`Catalog Price Schedule/
`
`Catalog Price Schedule/|Catalog Price Schedule/
`Product
`
`Number Page Number
`Number Page Number
`Number Page Number
`
`
`
`
`
`
`
`SB-127 B-60/49|NB-127 B-90/50
`B-21/48
`Cloxacillin
`
`
`
`
`“SB-155 A-60/46 |NB+155 -A90I47
`|Bte521/45
`
`
`
`
`G-301
`B-21/48
`
`
`
`SG-301 B-60/49|NG-301 B-90/50
`Cortexolone
`
`
`
`
`SG-311 B-60/49 | NG-311_B-90/50.
`
`“lean” Bane!
`
`
`
`
`G11
`A21/45
`
`
`
`
`
`SG-111 A-60/46|NG-111 A-90/47
`Corticosterone
`
`
`
`
`
`
`SG-171 A60/46|NG-171 A-90/47.
`“Corticosterone21-Acetate
`21/45
`
`
`
`
`
`
`Cortisone B-21/48|SG-121 B-60/49|NG-121 B-90/50
`
`
`
`
`
`
`~ Cortisone Acetate B-21/48|SG-181 B-60/49 | NG-181 B-90/50
`
`
`
`
`
`
`
`
`(-)Cotinine A-21/45|SK-124 A-60/46|NK-124K-124 A-90/47
`
`
`
`
`
`
`
`
`‘Coumarin(1,2 Benzopyrone): C-60/52|NC-112—C-90/53.C-21/51.| SC-112
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Cromolyn B-21/48|SC-195 B-60/49|NC-195 B-90/50
`
`
`
`
`Crotaline ae D-21/54|SK-125 D-60/55|NK-125 D-90/56
`
`
`
`
`
`
`
`
`
`
`
`Cyclizine A-21/45|SC-108 A-60/46|NC-108C-108 A-90/47
`
`
`
`
`
`
`
`Cyclophosphamide (Cytoxan) A-21/45|SZ-150 A-60/46
`
`
` NZ-150
`A-90/47
`
`
`
`
`
`
`B-90/50
`
`D-Cycloserine B-21/48|SB-128 B-60/49
`
`NB-128
`
`
`
`
`
`
`
`
`oymain D-21/54|SC-382 D-60/55|NC-382 D-90/56
`
`
`
`
`
`‘Byproheptadiia A-21/45|SC-481 A-60/46|NC-481 A-90/47
`
`
`
`
`
`: CyproteroneAcetate E-60/58.|NC-114—E-90/59E-21/57.| SC-114
`
`
`
`
`
`
`
`
`
`
`
`
`
`DCysteine C-21/51|$Q-201 C-60/52|NQ-201Q-201 C-90/53
`
`
`
`
`
`
`
`
`— Ltysteine C-60/52|N@-211c-21/51 | $Q-211 C-90/53
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`D-Cystine D-21/54|SQ-221 D-60/55|NQ-221 D-90/56
`
`
`
`
`
`
`
`
`
`Cetin. C-21/51|SQ-231 C-60/52|NQ-231Q-231 C-90/53
`
`
`
`
`
`Cytarabine (Cytosine Arabinoside) D-21/54|SZ-160 D-60/55|NZ-160 D-90/56
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`“ cyisne E-21/57|SK-126 E-60/58|NK-126 E-90/59
`
`
`
`
`
`
`
`
`
`
`
`Cytosine C-21/51|SN-241 C-60/52|NN-241 C-90/53
`
`
`
`
`
`
`
`_ Danazol _-D-21/54|SP-251 D-60/55|NP-251P-251 D-90/56
`
`
`
` Daunorubucine
`
`
`
`H-21/60|SZ-170 H-60/61|NZ-170
`
`
`26
`
`a
`
`AstraZeneca Exhibit 2044 p. 32
`
`

`

`C-90/53
`
`‘ase 21-Day Release|60-Day Release|90-Day Release
`
`Catalog Price Schedule/|Catalog Price Schedule/|Catalog Price Schedule/
`Product
`Tae wee Le Uoae ee Lo RSTome ecmoe
`
`
`
`
`/50 B-60/49|NN-251oDewzaurea - SN-251 B-90/50
`
`50 aoeBromide
`|
`| pe.
`B-21/48 | SD-112
`150
`re BelroxamineMesylate— 25 |
`; ie poe Batid “s0-113 : ob ois
`W47 aDehydrocholesterol
`y 1
`C-21/51
`Sv-281
`
`var1| hydrocholicAcid. |D414 C211|sb-t14 c
`50
`Dehydroepiandrosterone (OHEA)
`-
`--B-21/48 | SA-111
`50
`fi Dehydroepiandrosterone Acetate oe st D-
`5 7B241/48 SD-115 B-6 Ag NI 1
`47
`| Dehydroepiandrosterone Sulfate
`-
`D-21/54. SD-116
`D-60/55 ND.
`153
`S 46-Dehydropregnenolone :
`E P-27 . -B-21/48 SP-271_ B-60/49 NP-2i 1BS
`
`
`
`
`50 B-21/48|SP-281“48-Dehydropregnenotone Acetate - B-60/49
`156
`|/16-Dehydroprogesterone
`261
`B-21/48 ‘SP-261
`-B-60/49 or p2 61B-90/50.
`/47
`Demeclocycline
`-
`B-21/48-
`SD-121
`B-60/49
`B-90/50
`
`147|}|?Deoxycholic Acid 10-2151 | $D-110 C-60/52 |ND-110C-90/53_
`
`
`
`
`/50 B-21/48|SM-111' Deoxycorticosterone (Doc) Me B-60/49 NM-114 B-90/50
`
`
`/56
`_Deoxycorticosterone Acetate (D0cA)
`| Met2t A-21/45- SM-121
`A-60/46. |NM-1 2h ‘A90/47.
`/47
`| Desipramine
`B-21/48
`SC-491
`B-60/49
`NC-491
`B-90/50
`p07.
`/59
`"Desoximetasone
`_D-21/54.| SD-107_D-60/55. ND-107 D-90/56
`.
`/53
`| Dexamethasone
`D-21/54
`SG-131
`D-60/55 NG-131
`D-90156
`
`
`
`15311|Dexamethasone 21-Acetate _p.21/54|$G-201| G201 _-60/55 | NG-201 _D-90/56
`
`
`
`
`
`/56 D-21/54|SD-108 D-60/55|ND-108Dexamethasone 21-Phosphate - D-90/56
`
`153|)|.Diaveridine 129 D-21/54| $B-129 D-60/55| NB-129D-90/56
`
`
`
`
`
`56 L-2163|SN-271 L-60/64|NN-271N’-0*Dibutyryladenosine- s L-90/65
`8.9 -Cyclic Monophosphate_
`.
`pe -
`I
`eee aiermscnete
`159
`_Diclofenac
`:
`1 B-21/48 | SX-135
`a
`_B-60/49 | NX-135 B-90/50
`
`
`
`
`
`/53 B-21/48|SB-156 B-60/49|NB-156Dicloxacillin - B-90/50
`
`"56|}|Dienestrol | etei c-2tist | SE-te1 ¢-60/52 | NE-181C-90/63.
`
`
`62 C-21/51|SE-191 C-60/52|NE-191Dienestrol Diacetate -
`
`
`
`
`|
`
`AstraZeneca Exhibit 2044 p. 33
`
`ALPHABETICAL PRODUCT LISTING
`
`| [ o
`
`s
`
`a D
`
`ose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`Product
`
`21-Day Release
`Catalog Price Schedule/
`Number Page Number
`
`60-Day Release
`Catalog Price Schedule/
`Number Page Number
`
`90-Day Release
`Catalog Price Schedule/
`Number Page Number
`
`
`
`NE-151 B-90/50||
` B-60/49
`SE-151
`Diethylstilbestrol (Des)
` B-21/48
`E-151
`Batibo|
`‘Cioe B28 |SC-196
`C271
`—-B-21/48
`SC-271
`
`B-60/49 |NC-196
`B-60/49
`
`NK-A27
`BorDihydrorotestosteroneee Controlied Substances Page 2
`Special Dosing For Immuno-Deficient Mice. See pages 78-80
`s“SeDinysiteseserone
`A90/47 |
`| A161A-21/45
`~A-60/46| NA-161
`SA-161.
`SeaControlled.Substancessat Beers
`SD-106
`D-60/55
`ND-106 D-90/56
`58-Dihydrotestosterone
`D-106
`“ST- 231
`_ 3,5-Diiodo-DL-Thyronine
`| 7-231=B-21/48
`NT-231
` B-90/50
`B-60/49
`
`SK-127
`
`E-60/58
`
`D-21/54
`
`aeaDimenhydrinate
`9,10-Ea-1,2.Benzanthracene
`
`Dipyrone
`—Disopyramide
`
`Disulfiram
`
`7-241
`
`B-21/48
`
`ST- 241
`
`B-60/49
`
`NT-241
`
`B-90/50
`
`C205
`
`C-21/51
`
`SC-205
`
`_C-60/52
`
`_NC-205
`
`C-90/53
`
`D-117
`
`A-21/45
`
`SD-117
`
`A-60/46
`
`ND-117
`
`A-90/47
`
`| D-101
`
`D-102
`‘| C500
`D-109
`
`| B-21/48
`
`C-21/51
` B-21/48
`C-21/51
`
`SD-101
`
`B-60/49
`
`ND-104
`
`B-90/50
`
`SD-102
`
`C-60/52
`
`ND-102
`
`C-90/53
`
`SC-500
`
`B-60/49
`
`NC-500
`
`B-90/50
`
`SD-109
`
`C-60/52
`
`ND-109
`
`C-90/53
`
`~C-501
`
`~——-B-21/48
`
`SC-501
`
`B-60/49
`
`NC-501
`
`B-90/50
`
`C-60/52
`
`NC-502
`
`C-90/53
`
`NC-271 B-90/50.ne
`B-90/50
`
`ae =
`DL-Dopa
`i _L-Dopa
`| c503=C-21/51
`C-60/52
`NC-503
`C-90/53
`SC-503
`Doparnines
`__Doxepin
`Doxycycline
`
`C-502
`
`C-21/51
`
`SC-502
`
`C151
`
`C-21/51
`
`SC-151
`
`C-60/52
`
`NC-151
`
` C-90/53
`
`B-60/49
`
`NC-325
`
` B-90/50
`
`| C325 B21/48
`
`SC-325
`
`B-168
`
` A-21/45
`
`SB- 168
`
`A-60/46
`
`NB-168
`
`A-90/47
`
`(ote
`
`C504 C-21/51
`
`SC-504
`
`C-60/52
`
`NC-504
`
`- -90/53
`
`Drofenine
`
`D103
`
`C-21/54
`
`SD-103
`
`C-60/52
`
`ND-103
`
`C-90/53
`
`Dropropizine
`
`|GEcdysone
`
`‘| D104
`
`A-21/45°
`
`-SD-104
`
`A-60/46
`
`ND-104
`
`A-90/47
`
`D-105
`
`C-21/51
`
`SD-105
`
`C-60/52
`
`ND-105
`
`C-90/53
`
`E-103
`
`H-21/60
`
`SE- 103
`
`H-60/61
`
`NE-103
`
`H-90/62
`
`Econazole
`
`B-181
`
`B-21/48
`
`SB-181
`
`B-60/49
`
`NB-181
`
`28
`
`AstraZeneca Exhibit 2044 p. 34
`
`

`

`ALPHABETICAL PRODUCT LISTING
`gaaraenaSeeee
`Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release|60-Day Release|90-Day Release
`~ Catalog Price Schedule/}Catalog Price Schedule/|Catalog Price Schedule/
`
`Produc